| A | B | C | D | E | F | G | H | I | J | K | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | |||||||||||
| 2 | Name | Indication | MOA | Approval | Economics | Price | 14.34 | ||||
| 3 | Elahere (mirvetuximab soravtansine) | FRalpha+-ovarian cancer | FR-ADC | Shares | 226.070419 | Q123 | |||||
| 4 | Phase | MC | 3241.8498084599996 | ||||||||
| 5 | IMGN151 | FR-ADC | Cash | 201.249 | Q123 | ||||||
| 6 | IMGC936 | Debt | 0 | Q123 | |||||||
| 7 | EV | 3040.60080846 | |||||||||
| 8 | |||||||||||
| 9 | |||||||||||
| 10 | CEO: Mark Enyedy | ||||||||||
| 11 | CCO: Isabel Kalofonos |